Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants:: A randomized, placebo-controlled trial

被引:98
作者
Macete, Eusebio
Aide, Pedro
Aponte, John J.
Sanz, Sergi
Mandomando, Inacio
Espasa, Mateu
Sigauque, Betuel
Dobano, Carlota
Mabunda, Samuel
DgeDge, Martinho
Alonso, Pedro
Menendez, Clara
机构
[1] Univ Barcelona, Ctr Int Hlth, Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer, E-08036 Barcelona, Spain
[2] Manhica Hlth Res Ctr, Manhica, Mozambique
[3] Minist Hlth, Natl Directorate Hlth, Maputo, Mozambique
[4] Minist Hlth, Natl Inst Hlth, Maputo, Mozambique
[5] Minist Hlth, Natl Malaria Control Program, Maputo, Mozambique
[6] Minist Hlth, Dept Community Hlth, Maputo, Mozambique
关键词
D O I
10.1086/505431
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is an urgent need to deploy and develop new control tools that will reduce the intolerable burden of malaria. Intermittent preventive treatment in infants (IPTi) has the potential to become an effective tool for malaria control. Methods. We performed a randomized, double-blind, placebo-controlled trial of sulfadoxine-pyrimethamine (SP) treatment in 1503 Mozambican children. Doses of SP or placebo were given at 3, 4, and 9 months of age. The intervention was administered alongside routine vaccinations delivered through the Expanded Program on Immunization (EPI). Hematological and biochemical tests were done when infants were 5 months old. Morbidity monitoring through a hospital-based passive case-detection system was complemented by cross-sectional surveys when infants were 12 and 24 months old. Results. IPTi was well tolerated, and no adverse events associated with SP were documented. During the first year of life, intermittent SP treatment reduced the incidence of clinical malaria by 22.2% (95% confidence interval [CI], 3.7% - 37.0%;) and the rate of hospital admissions by 19% (95% CI, 4.0%-31.0%;). Pp. 020 Pp. 014 Although the incidence of severe anemia (packed cell volume of < 25%) did not differ significantly between the 2 groups (protective effect, 12.7% [95% CI, - 17.3% to 35.1%];), there was a significant reduction in hospital P=. 36 admissions for anemia during the month after dosing for both the first and second dose. The serological responses to EPI vaccines were not modified by the intervention. Conclusions. IPTi with SP has been shown to moderately reduce the incidence of clinical malaria in Mozambican infants without evidence of rebound after stopping the intervention or of interactions with EPI vaccines. Its recommendation as a malaria control strategy in Mozambique needs to be balanced against the scarcity of affordable control tools and the burden of malaria in children.
引用
收藏
页码:276 / 285
页数:10
相关论文
共 25 条
[1]   Efficacy of chloroquine, amodiaquine, sulphadoxine- pyrimethamine and combination therapy with artesunate in Mozambican children with non-complicated malaria [J].
Abacassamo, F ;
Enosse, S ;
Aponte, JJ ;
Gómez-Olivé, FX ;
Quintó, L ;
Mabunda, S ;
Barreto, A ;
Magnussen, P ;
Ronn, AM ;
Thompson, R ;
Alonso, PL .
TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2004, 9 (02) :200-208
[2]   Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial [J].
Alonso, PL ;
Sacarlal, J ;
Aponte, JJ ;
Leach, A ;
Macete, E ;
Milman, J ;
Mandomando, I ;
Spiessens, B ;
Guinovart, C ;
Espasa, M ;
Bassat, Q ;
Aide, P ;
Ofori-Anyinam, O ;
Navia, MM ;
Corachan, S ;
Ceuppens, M ;
Dubois, MC ;
Demoitié, MA ;
Dubovsky, F ;
Menéndez, C ;
Tornieporth, N ;
Ballou, WR ;
Thompson, R ;
Cohen, J .
LANCET, 2004, 364 (9443) :1411-1420
[3]   RANDOMIZED TRIAL OF EFFICACY OF SPF66 VACCINE AGAINST PLASMODIUM-FALCIPARUM MALARIA IN CHILDREN IN SOUTHERN TANZANIA [J].
ALONSO, PL ;
SMITH, T ;
SCHELLENBERG, JRMA ;
MASANJA, H ;
MWANKUSYE, S ;
URASSA, H ;
DEAZEVEDO, IB ;
CHONGELA, J ;
KOBERO, S ;
MENENDEZ, C ;
HURT, N ;
THOMAS, MC ;
LYIMO, E ;
WEISS, NA ;
HAYES, R ;
KITUA, AY ;
LOPEZ, MC ;
KILAMA, WL ;
TEUSCHER, T ;
TANNER, M .
LANCET, 1994, 344 (8931) :1175-1181
[4]  
Beales PF, 2000, T ROY SOC TROP MED H, V94, pS1
[5]  
FLOREZL J, 2003, FARMACOLOGIA HUMANA
[6]  
Geerligs PDP, 2003, B WORLD HEALTH ORGAN, V81, P205
[7]  
Greenwood B, 2004, AM J TROP MED HYG, V70, P1
[8]   THE INFLUENCE OF MALOPRIM CHEMOPROPHYLAXIS ON CELLULAR AND HUMORAL IMMUNE-RESPONSES TO PLASMODIUM-FALCIPARUM ASEXUAL BLOOD-STAGE ANTIGENS IN SCHOOLCHILDREN LIVING IN A MALARIA ENDEMIC AREA OF MOZAMBIQUE [J].
HOGH, B ;
THOMPSON, R ;
LOBO, V ;
DGEDGE, M ;
DZIEGIEL, M ;
BORRE, M ;
GOTTSCHAU, A ;
STREAT, E ;
SCHAPIRA, A ;
BARRETO, J .
ACTA TROPICA, 1994, 57 (04) :265-277
[9]  
INDEPTH Network, 2002, POP HLTH DEV COUNTR
[10]  
*IPTI, INT PREV TREATM INF